Managers / Q1 2024 · view latest →
Bellevue Group AG
CIK 0001674546 · THEATERSTRASSE 12, ZURICH, CH-8001 · 41 44 267 67 77
Reported Value
$6.6B
Q1 2024
Positions
208
Filings on Record
30
2019–present window
Filed
May 15, 2024
original filing
Summary
Bellevue Group Ag reported $6.6B in U.S.-listed holdings across 208 positions for Q1 2024.
Compared with Q4 2023, the fund opened 23 new positions and exited 15.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
Composition data arrives with ticker enrichment.
Quarter-over-Quarter Changes full breakdown →
Holdings — Q1 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $4.2B | 167 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $5.3B | 213 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $4.8B | 186 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $4.5B | 175 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $4.5B | 177 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $5.2B | 193 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $6.2B | 196 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $6.2B | 204 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $6.6B | 208 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $6.5B | 202 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $6.2B | 196 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $7.0B | 198 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $6.9B | 202 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $7.53T | 215 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $7.0B | 217 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $7.1B | 214 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $8.6B | 220 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $9.7B | 235 | Feb 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $9.9B | 265 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $10.2B | 262 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $9.5B | 260 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $8.7B | 266 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $7.2B | 261 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $7.1B | 235 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $5.2B | 239 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $6.3B | 239 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $5.4B | 236 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $5.9B | 219 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.8B | 138 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $1.5B | 138 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 3 additional managers.
- BB Biotech AG28-06964
- Bellevue Asset Management AG28-16892
- Bellevue Asset Management (UK) Ltd.28-20408
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.